News
Hosted on MSN1mon
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugsPeople taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.
Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.
Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...
BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
It’s a shot at better health that comes with a promise to help shed the pounds. Demand for drugs like Ozempic, Wegovy, Mounjaro and Zepbound continues to grow. FILE – Donna ...
In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...
Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback